Webinar: antibody patents in Europe and beyond

Antibody patenting can be a minefield for IP practitioners if they lack the most up-to-date knowledge about the best way to approach a patent application. Antibody experts and European patent attorneys Tom Leonard, Alison Care and Dave Wortley from law firm Kilburn & Strode joined WIPR group editor Tom Phillips for a webinar on the latest developments in antibody patenting yesterday, August 5.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

Part II: The race to replace semaglutide heats up

23 March 2026 With Novo Nordisk's core semaglutide patent expired in India last week, the company that built one of the most successful drugs in pharmaceutical history is already fighting on a new front. So what comes next?

Big Pharma

Sandoz strikes fresh biosimilar deal with South Korean biotech

19 March 2026 The Swiss generics giant secures global commercialisation rights as partnership targets multi-billion-dollar loss-of-exclusivity opportunity.

Big Pharma

INTA: ‘New normal’ for in-house counsel as budgets fall

16 March 2026 Research from the International Trademark Association finds in-house counsel taking on more strategic work while facing shrinking budgets, prompting a shift towards alternative billing and greater use of AI.

More features

Gilead to pay up to $5bn for antibody-drug conjugates push

Closing the women's health gap offers ‘benefits for all’

Bausch reaches deal with competitor over IBS drug generic

European patent offices raise fees

UPC refuses early knockout in Illumina–Element dispute

Argentina’s patent reset: Why pharma can no longer ignore Latin America's second-largest market

IndiaMart v CDSCO: A test of intermediary liability

UPC appeals court upholds Abbott injunction in glucose monitoring patent dispute

Webinar: antibody patents in Europe and beyond

More on this story

Editor's picks

Editor's picks

More features